Article

Disruption of COX-2 modulates gene expression and the cardiac injury response to doxorubicin

Royal College of Surgeons in Ireland, Dublin, Leinster, Ireland
AJP Heart and Circulatory Physiology (Impact Factor: 4.01). 09/2006; 291(2):H532-6. DOI: 10.1152/ajpheart.00863.2005
Source: PubMed

ABSTRACT To determine the role of cyclooxygenase (COX)-2 in anthracycline-induced cardiac toxicity, we administered doxorubicin (Dox) to mice with genetic disruption of COX-2 (COX-2-/-). After treatment with Dox, COX-2-/- mice had increased cardiac dysfunction and cardiac cell apoptosis compared with Dox-treated wild-type mice. The expression of the death-associated protein kinase-related apoptosis-inducing protein kinase-2 was also increased in Dox-treated COX-2-/- animals. The altered gene expression, cardiac injury, and dysfunction after Dox treatment in COX-2-/- mice was attenuated by a stable prostacyclin analog, iloprost. Wild-type mice treated with Dox developed cardiac fibrosis that was absent in COX-2-/- mice and unaffected by iloprost. These results suggest that genetic disruption of COX-2 increases the cardiac dysfunction after treatment with Dox by an increase in cardiac cell apoptosis. This Dox-induced cardiotoxicity in COX-2-/- mice was attenuated by a prostacyclin analog, suggesting a protective role for prostaglandins in this setting.

0 Followers
 · 
87 Views
  • Source
    • "The classification of chemotherapy drugs, cardiac side-effects, underlying mechanisms, associated risk factors, as well as the management of cancer chemotherapy are summarized by Jean-Jacques Monsuez, [28], as indicated in the paper, cancer chemotherapy induces cardiomyocyte damage through oxidative stress (ROS production ). Several studies suggest iloprost protects against DOXinduced cardiomyocyte injury in vitro and in vivo without compromising tumor suppression [30] [31] [32]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Prostacyclin (PGI(2)) and its analogues protect from cardiovascular disease through pleiotropic effects such as vasodilation, inhibition of platelet aggregation, leukocyte adhesion, and vascular smooth muscle cell (VSMC) proliferation. Additionally, prostacyclin synthase (PGIS) and PGI(2) also possess anti-cancer properties. As of late (2009-2010), numerous studies have identified the deleterious side-effects of chemotherapy on the cardiovascular system, which have been deemed as a serious clinical issue. Cardiomyocyte damage, induced by oxidative stress, is one of the clinical consequences caused by routine cancer chemotherapy. Previous studies indicate iloprost, a PGI(2) analogue, can protect against doxorubicin-induced (DOX) cardiomyocyte injury in vitro and in vivo without compromising tumor suppression. Therefore, we hypothesize PGI(2) can be used as a cardioprotective supplement to attenuate the damaging cardiac effects caused by the traditional cancer chemotherapy regimen.
    Medical Hypotheses 02/2011; 76(5):695-6. DOI:10.1016/j.mehy.2011.01.036 · 1.07 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In der pädiatr. Onkologie gewinnt die Reduktion unerwünschter Effekte bei gleicher Therapieeffizienz Bedeutung. PPAR-Agonisten, verträgliche Medikamente zur Behandlung v. Lipid- und Kohlenhydratstoffwechselkrankheiten, zeigen bei einigen Tumoren antiproliferative Wirksamkeit. Da für pädiatrische Tumoren kaum Daten vorliegen, werden Effekte v. PPARalpha u. -gamma-Agonisten (Fenofibrat/Rosiglitzon) auf pädiatr. Tumorzelllinien allein u. kombiniert mit Doxorubicin mittels MTT-Assay untersucht. Durch PCR wird die Expression d. Rezeptoren analysiert u. Rezeptorabhängige von -unabhängigen Effekten differenziert. V.a. Rezeptorunabhängige antiproliferative Effekte spielen eine Rolle. Bei ähnlicher Wirkung der Einzelsubstanzen ist Rosi toxischer. Feno wirkt antagonistisch zu Doxo, während Effekte v. Rosi u. Doxo synergistisch o. additiv sind. Rosi reduziert die Dosis von Doxo bei gleicher Wirksamkeit, was für Einsetzbarkeit von PPARgamma-Agonisten in d. pädiatr. Krebstherapie spricht.
  • Article: Drak2
    AfCS-Nature Molecule Pages 01/2007; DOI:10.1038/mp.a000791.01
Show more